References
- Wolf PL. Interpretation of lactate dehydrogenase isoenzyme. Clin Lab Med 1986;6(3):541–545.
- Koukourakis MI, Giatromanolaki A, Sivridis E. Tumour and angiogenesis reserch group. Lactate dehydrogenase isoen-zymes 1 and 5: Differential expression by neoplastic and stromal cells in non-small cell lung cancer and other epithelial malignant tumours. Tumour Biol 2003;24(4):199–202.
- Carcamo C, Pallares E, Rubi J, Cesar JM. Lactate dehydrogenase isoenzymes in patients with essential thrombo-cythemia. Thromb Res 1993;70(2):111–116.
- Dumontet C, Drai J, Bienvenu J, Berard EN, Thieblemont C, Bouafia F, et al. Profiles and prognostic values of LDH isoenzymes in patients with non-Hodgkin’s lymphoma. Leukemia 1999;13(5):811–817.
- Hoffbrand AV, Kremenchuzky S, Butterworth PJ, Mollin DL. Serum lactic dehydrogenase activity and folate deficiency in myelosclerosis and other haematological diseases. Br Med J 1966;1:577–581.
- Everse J, Kaplan NO. Lactate dehydrogenase: Structure and function. In: Alton M, editor. Advances in enzymology., 37 New York, NY: John Wiley and Sons; 1973. p 61–133.
- Wilson AC, Kaplan NO, Levine C, Pesce A, Reichlin M, Allison WS. Evolution of lactic dehydrogenases. Fed Proc 1964;23:1258–1266.
- Krieg AF, Rosenblum LJ, Henry JB. Lactate deydrogenase isoenzymes a comparison of pyruvate-to-lactate and lactate-to-pyruvate assays. Chin Chem 1967;13:196–203.
- Wroblewski F, Gregory KF. Lactic dehydrogenase isoenzymes and their distribution in normal tissues and plasma and in disease states. Ann NY Acad Sci 1961;94:912–932.
- Thiele J, Kvasnicka HM. Chronic myeloproliferative disorders. The new WHO classification. Pathologe 2001;22(6):429–443.
- Spivak JL. The chronic myeloproliferative disorders: Clonality and clinical heterogeneity. Semin Hematol 2004; 41(2 Suppl 3):1–5.
- Michiels JJ, Thiele J. Clinical and pathological criteria for the diagnosis of essential thrombocythemia, polycythemia vera and idiopathic myelofibrosis (agnogenic myeloid metaplasia). Int J Hematol 2002;76(2):133–145.
- Jaffe ES, Harris NL, Stein H, Vardinam JW, editors. World health organization classification of tumors. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2001.
- Amador E, Dorfman LE, Wacker WEC. Serum lactic dehydrogenase: An analytical assessment of current assay. Clin Chem 1963;12:391–399.
- Passamonti F, Malabarda L, Orlandi E, Barate C, Canevari A, Brusamolino E, et al. Polycythemia vera in young patients: A study on the long-term risk of thrombosis, myelofibrosis and leukemia. Haematology 2003;88(1):13–18.
- van Genderen PJ, Troost MM. Polycythemia vera and essential thrombocythaemia in the elderly. Drugs Aging 2000;17(2): 107–119.
- Thiele J, Kvasnicka HM, Zankovich R, Diehl V. Relevance of bone marrow features in the differential diagnosis between essential thrombocythemia and early stage idiopathic myelofi-brosis. Haematology 2000;85(11):1126–1134.
- Cervantes F, Alvarez-Larran A, Talarn C, Gomez M, Monsterrat E. Myelofibrosis with myeloid metaplasia follow-ing essential thrombocythaemia: Actuarial probability, pre-senting characteristics and evolution in a series of 195 patients. Br J Haematol 2002;118(3):786–790.
- Barosi G. Myelofibrosis with myeloid metaplasia: Diagnostic definition and prognostic classification for clinical studies and treatment guidelines. J Chin Onc 1999;17(9):2954–2970.
- Spivak JL, Barosi G, Rognoni G, Barbui T, Finazzi G, Marchiali R, Marchetti M. Chronic myeloproliferative disorders. Haematology 2003; (ASH):200–224.